American Association for Cancer Research
cir-22-0996_figure_s12_suppsf12.png (791.67 kB)

Figure S12 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

Download (791.67 kB)
posted on 2023-06-22, 19:20 authored by Renee Maria Saliby, Talal El Zarif, Ziad Bakouny, Valisha Shah, Wanling Xie, Ronan Flippot, Thomas Denize, M. Harry Kane, Katrine N. Madsen, Miriam Ficial, Laure Hirsch, Xiao X. Wei, John A. Steinharter, Lauren C. Harshman, Ulka N. Vaishampayan, Mariano Severgnini, David F. McDermott, Gwo-Shu Mary Lee, Wenxin Xu, Eliezer M. Van Allen, Bradley A. McGregor, Sabina Signoretti, Toni K. Choueiri, Rana R. McKay, David A. Braun

Supplementary Figure 12



Renal cell carcinoma (RCC) of variant histology comprises approximately 20% of kidney cancer diagnoses, yet the optimal therapy for these patients and the factors that impact immunotherapy response remain largely unknown. To better understand the determinants of immunotherapy response in this population, we characterized blood- and tissue-based immune markers for patients with variant histology RCC, or any RCC histology with sarcomatoid differentiation, enrolled in a phase II clinical trial of atezolizumab and bevacizumab. Baseline circulating (plasma) inflammatory cytokines were highly correlated with one another, forming an “inflammatory module” that was increased in International Metastatic RCC Database Consortium poor-risk patients and was associated with worse progression-free survival (PFS; P = 0.028). At baseline, an elevated circulating vascular endothelial growth factor A (VEGF-A) level was associated with a lack of response (P = 0.03) and worse PFS (P = 0.021). However, a larger increase in on-treatment levels of circulating VEGF-A was associated with clinical benefit (P = 0.01) and improved overall survival (P = 0.0058). Among peripheral immune cell populations, an on-treatment decrease in circulating PD-L1+ T cells was associated with improved outcomes, with a reduction in CD4+PD-L1+ [HR, 0.62; 95% confidence interval (CI), 0.49–0.91; P = 0.016] and CD8+PD-L1+ T cells (HR, 0.59; 95% CI, 0.39–0.87; P = 0.009) correlated with improved PFS. Within the tumor itself, a higher percentage of terminally exhausted (PD-1+ and either TIM-3+ or LAG-3+) CD8+ T cells was associated with worse PFS (P = 0.028). Overall, these findings support the value of tumor and blood-based immune assessments in determining therapeutic benefit for patients with RCC receiving atezolizumab plus bevacizumab and provide a foundation for future biomarker studies for patients with variant histology RCC receiving immunotherapy-based combinations.

Usage metrics

    Cancer Immunology Research





    Ref. manager